News
Events
In a significant move, we've established a center of pharmaceutical development in Xizhi, New Taipei City, Taiwan.
Certificate / License
Shiner obtains the necessary building permit to commence construction of a Western pharmaceutical formulation plant in the Hsinchu Science Park.
Certificate / License
Shiner's pms-Methylphenidate ER 18mg Tablets receives TFDA approval for the treatment of ADHD. (ANDA, API: methylphenidate hydrochloride)
Certificate / License
Shiner's Phenbuty 500mg Tablets receives TFDA approval. (NDA, the orphan drug, API: sodium phenylbutyrate)
Certificate / License
Shiner's pms-Methylphenidate ER 36mg Tablets receives TFDA approval for the treatment of ADHD. (ANDA, API: methylphenidate hydrochloride)
Certificate / License
Shiner receives approval and plans to establish a formulation plant in Hsinchu Science Park Zhunan Campus.
Certificate / License
L-Carnit "Shiner" Injection 1g/5ml receives TFDA approval. (NDA, the orphan drug, API: levocarnitine)
Certificate / License
Shiner's Shilifil 100mg F.C. Tablets receives TFDA approval for the treatment of erectile dysfunction. (ANDA, API: sildenafil citrate)
Certificate / License
Shiner's "GelX" Oral Gel (Non-sterile) receives TFDA approval. (Medical Device, Liquid bandage)
Certificate / License
Shiner's Haxasin XL Tablets 4mg receives TFDA approval for the treatment of the symptoms of an enlarged prostate, benign prostatic hyperplasia or BPH.
← 1234 →
